CTPartners Executive Search (NYSE: CTP) 83.8% LOWER; announced that the exclusivity period for its negotiations with DHR International Inc. regarding an acquisition of the Company expired late last week with no definitive agreement for the sale of the Company as a whole having been reached.
Vical (NASDAQ: VICL) 47.2% LOWER; announced top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients. The trial enrolled patients